遗传因素与肠道微生物组指导炎症性肠病微生物疗法的开发
本综述回顾了与炎症性肠病(IBD)相关的遗传变异及其对肠道微生物组、免疫应答和疾病发病机制的影响,并讨论了肠道微生物组通过微生物抗原、佐剂和代谢产物影响肠道黏膜发育与功能及肠道炎症反应,进而综述了用于治疗IBD的微生物疗法及工程化患者肠道微生物组的潜力,以及遗传因素与肠道微生物组相互作用研究的进展和微生物疗法开发面临的挑战。
要点
- 肠道微生物组失衡及对肠道细菌的异常免疫应答与人类IBD和小鼠结肠炎相关。
- IBD相关遗传变异影响肠道微生物组、免疫应答和疾病发病机制。
- 肠道微生物组通过微生物抗原、佐剂和代谢产物影响肠道黏膜发育与功能及肠道炎症反应。
核心结论
- 操纵微生物组的策略可能用于IBD的治疗。
研究设计与样本
- 综述,回顾了IBD相关遗传变异及其对肠道微生物组、免疫应答和疾病发病机制的影响,以及微生物疗法和工程化肠道微生物组的潜力。
主要发现
- 肠道微生物组失衡及对肠道细菌的异常免疫应答可破坏稳态,与人类IBD和小鼠结肠炎相关。
- 肠道微生物组包括微生物抗原、佐剂和代谢产物,影响肠道黏膜的发育和功能,从而影响肠道炎症反应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The intestinal microbiota is a dynamic community of bacteria, fungi, and viruses that mediates mucosal homeostasis and physiology. Imbalances in the microbiome and aberrant immune responses to gut bacteria can disrupt homeostasis and are associated with inflammatory bowel diseases (IBDs) in humans and colitis in mice. We review genetic variants associated with IBD and their effects on the intestinal microbiome, the immune response, and disease pathogenesis. The intestinal microbiome, which includes microbial antigens, adjuvants, and metabolic products, affects the development and function of the intestinal mucosa, influencing inflammatory responses in the gut. Therefore, strategies to manipulate the microbiome might be used in treatment of IBD. We review microbe-based therapies for IBD and the potential to engineer patients' intestinal microbiota. We discuss how studies of patients with IBD and mouse models have advanced our understanding of the interactions between genetic factors and the gut microbiome, and challenges to the development of microbe-based therapies for IBD.
引用
- Cohen LJ, Cho JH, Gevers D, et al. Genetic Factors and the Intestinal Microbiome Guide Development of Microbe-Based Therapies for Inflammatory Bowel Diseases. Gastroenterology. 2019. PMID: 30880022. doi:10.1053/j.gastro.2019.03.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。